A PD-1/LAG-3 bispecific antibody, RO7247669/Tobemstomig is in early Phase I/II clinical trial for use in patients with melanoma, NSCLC, RCC and solid tumors (NCT05116202, NCT05419388, NCT05775289, NCT05805501, NCT04140500). Here, LAG3 is linked to non-small cell lung carcinoma.